Inactive Instrument

Sienna Cancer Diagnostics Limited

Equities

SDX

AU000000SDX1

Sienna Signs Lease for New Premises to Facilitate the Execution of Its Strategic Goal to Become an Ivd Hub

October 07, 2019 at 07:07 pm EDT

Sienna Cancer Diagnostics Ltd. is expanding its operations and moving to a new location adjacent to CSIRO and the Monash Technology Precinct. Sienna's new premises will contain office space, research and development laboratories, as well as a manufacturing suite and warehouse facility for the SIEN-NET product line which is currently in development.

Latest news about Sienna Cancer Diagnostics Limited

BARD1 Life Sciences Limited completed the acquisition of Sienna Cancer Diagnostics Limited from Merchant Funds Management Pty Ltd and other shareholders.	20-07-27	CI
Sienna Cancer Diagnostics Announces Change of Registered Office	20-06-26	CI
Sienna Cancer Diagnostics Limited Announces Distribution Agreement with Aenorasis S.A	20-06-18	CI
Sienna Cancer Diagnostics Appoints Triolab AB Exclusive Distributor in Sweden	20-06-01	CI
Sienna Cancer Diagnostics Limited Announces Distribution Agreement with Zotal Ltd	20-05-20	CI
Sienna Cancer Diagnostics Ltd. Appoints Scientle Innovations as its Exclusive Distributor in New Zealand	20-05-05	CI
Sienna Cancer Diagnostics Ltd H Enters into an Exclusive Worldwide Licence Agreement with the University of Adelaide to Develop and Commercialise Unique Cancer Probe, SubB2M	20-04-19	CI
BARD1 Life Sciences Limited entered into a merger implementation agreement to acquire Sienna Cancer Diagnostics Limited for AUD 24.7 million.	20-04-07	CI
Sienna Cancer Diagnostics Limited Appoints Geoff Mccaughan to Its Recently Formed Clinical Advisory Board	20-03-15	CI
Sienna Cancer Diagnostics Limited Reports Earnings Results for the Half Year Ended December 31, 2019	20-02-20	CI
Sienna Cancer Diagnostics Limited Appoints Immuno Diagnostic Oy as an Exclusive Distributor in Finland	20-02-05	CI
Sienna Cancer Diagnostics Limited Appoints Tony Di Pietro as a Director of its Board	20-02-05	CI
Sienna Cancer Diagnostics Limited Announces Clinical Advisory Board Appointments	20-01-29	CI
Sienna Cancer Diagnostics Ltd Announces the Initiation of South Korean Clinical Study Utilising the Company's Novel Adjunct Urine Cytology Test, the hTERT test	20-01-21	CI
Sienna Cancer Diagnostics Ltd Announces That Non-Executive Director, David J. Earp, Jd, Has Stepped Down Effective 14 November 2019	19-11-13	CI
Sienna Cancer Diagnostics Limited Enters into an Agreement with VivaZome Therapeutics Pty Ltd	19-11-07	CI
Sienna Cancer Diagnostics Ltd and Minomic International Ltd Enter Collaboration Agreement	19-10-29	CI
Sienna Cancer Diagnostics Limited Announces Change of CEO	19-10-15	CI
Sienna Signs Lease for New Premises to Facilitate the Execution of Its Strategic Goal to Become an Ivd Hub	19-10-07	CI
Sienna Cancer Diagnostics Ltd Reports Earnings Results for the Full Year Ended June 30, 2019	19-08-22	CI
24,426,629 Ordinary Shares of Sienna Cancer Diagnostics Limited are subject to a Lock-Up Agreement Ending on 3-AUG-2019.	19-08-02	CI
4,500,000 Options of Sienna Cancer Diagnostics Limited are subject to a Lock-Up Agreement Ending on 3-AUG-2019.	19-08-02	CI
Sienna Cancer Diagnostics Ltd Announces the Grant of a Second Patent in China for the Liquid Biopsy Sample Preparation Technology, SIEN-NETTM	19-05-21	CI
Sienna Cancer Diagnostics Ltd Appoints Inside Diagnósticos as the Company's Exclusive Distribution Partner for Brazil	19-03-17	CI
Sienna Cancer Diagnostics Limited Furthers Its Global Expansion with Distributor for Singapore	19-02-03	CI

Chart Sienna Cancer Diagnostics Limited

Duration

Period

More charts

Company Profile

Sienna Cancer Diagnostics Limited is an Australia-based biotechnology company. The Company is focused on the development and commercialization of novel in vitro diagnostic (IVD) tests for detection and monitoring of cancer. The Company manufactures IVD products for pathology laboratories to use in testing services. The Company's product Anti-human telomerase reverse transcriptase (hTERT) antibody (SCD-A7) is based on a technology for the detection of biomarker telomerase.The hTERT can be used in pathology labs. Anti-hTERT is targeted against hTERT protein component of the telomerase complex which acts to extend and maintain telomeres in cells.

Sector

More about the company